Ozeki Y, Masaki T, Kamata A, Miyamoto S, Yoshida Y, Okamoto M, et al
April 1, 2025: MDL Against Ozempic and Other GLP-1s Top 1,600 in April As of April 1, 2025, there are 1,685 active lawsuits pending against Novo Nordisk and other pharmaceutical companies that sold GLP-1 drugs like Ozempic
21 ROI Analysis: The Vial Strategy Pricing Floor Your greatest threat isnt the FDA
You can do these through your Blue Access for Members SM account
9 Common Questions." FDA: "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," "Label: Foundayo (Orforglipron)." National Association of Insurance Commissioners: "Does Insurance Cover Prescription Weight Loss Injectables?" University of Chicago Medicine: "Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns." Massachusetts General Hospital: "Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss." UT Southwestern Medical Center: "Weight-loss medications: The 5 most-asked questions." University of Kansas Health System: "Surprises and Concerns About GLP-1 Medications." Brown University Health: "Compounded Weight Loss Medications: What are They and What are Their Risks?" University of Missouri Health: "Thinking About Microdosing GLP-1
When these small steps are consistent, GLP-1 medications become far more effective
